Published in

Elsevier, Vascular Pharmacology, 6(44), p. 508-512

DOI: 10.1016/j.vph.2006.03.004

Links

Tools

Export citation

Search in Google Scholar

Does rapid dose titration affect the hepatic safety profile of Bosentan?

Journal article published in 2006 by J. Suntharalingam, D. Hodgkins, Fh H. Cafferty ORCID, Rj J. Hughes, J. Pepke-Zaba
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Red circle
Postprint: archiving forbidden
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Bosentan, a dual endothelin receptor antagonist, has proven efficacy in pulmonary hypertension. Due to an association with hepatic dysfunction, it is typically initiated at a sub-therapeutic dose for 4 weeks before titration to a therapeutic dose. At our institution some patients have undergone rapid titration, to potentially benefit from therapy earlier. This study assesses the impact of this practice on hepatic safety.